Moleculin Biotech, Inc. Balance Sheet
MBRX|10 years of annual SEC 10-K data (FY2016-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 10 fiscal years. All figures from audited SEC 10-K filings.
Moleculin Biotech, Inc. had $22M in total assets and $11M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -3.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.9M | $4.3M | $23.6M | $43.1M | $70.9M | $15.2M | $10.7M | $7.1M | $5.0M | $28.1K |
| Accounts Receivable | - | - | - | - | - | - | $1.0K | - | - | - |
| Current Assets | $9.7M | $5.2M | $26.3M | $45.6M | $72.5M | $17.2M | $13.5M | $8.0M | $8.3M | $5.2M |
| PP&E (Net) | $78.0K | $159.0K | $272.0K | $275.0K | $338.0K | $483.0K | $316.0K | $463.0K | $33.0K | $23.1K |
| Total Assets | $22.1M | $16.9M | $38.2M | $57.4M | $84.1M | $29.0M | $25.2M | $19.6M | $19.5M | $16.4M |
| Current Liabilities | $6.9M | $5.4M | $6.8M | $4.8M | $3.6M | $2.9M | $3.6M | $3.9M | $2.2M | $1.3M |
| Shareholders' Equity | $11.2M | $26.1M | $52.2M | $79.0M | $17.8M | $15.6M | $14.3M | $17.1M | $15.0M | -$744.7K |